NAMA Shortcuts
Member Directory
Best of NAMA 2012
Upcoming Events
Chapters
Agri-Marketing Conf
More NAMA












9 MONTHS: SANOFI SALES DOWN 7%, NET INCOME DROPS 25%
Source: Sanofi news release

To view the complete report, click here.

Commenting on the Group's performance in Q3 2013, Sanofi Chief Executive Officer, Christopher A. Viehbacher said,
"The third quarter marks an inflection point for Sanofi as the impact of the patent cliff ended in August. As a result, we returned to sales growth in September. Our growth platforms grew 5.5% in the third quarter despite the shortage of pertussis-containing vaccines in the U.S. until mid-October, the impact of the market slowdown in China and our recovering generics business in Brazil.

Growth platforms now represent 75% of our sales. We continue to make strong progress in R&D with recent approvals for Aubagio® and Lemtrada™ in EU, Nasacort® Allergy 24HR for OTC use and NexGard™ in the U.S. We also released positive results for the first Phase III with alirocumab and for a large study with Fluzone® High-Dose."

Sales of Animal Health products were €458 million, down 6.4% in the third quarter. Year-to-date sales of Animal Health products totaled €1,541 million, down 5.0%.

Sales of the Companion Animals franchise were €279 million, a decrease of 10.0% in the third-quarter reflecting a tough base for comparison for Heartgard® which benefited from a competitor supply issue in the third quarter of 2012 and increased Frontline® competition from prescription-only products and branded generic of fipronil.

In September, the U.S. Food and Drug Administration approved NexGard™ (afoxolaner) Chewables for the treatment and prevention of flea infestations, and treatment and control of the American Dog tick in adult dogs and puppies, for one month. NexGard™, which has demonstrated excellent efficacy at the low dose, is the first and only soft beef-flavored chew approved to kill both fleas and ticks.

It contains the novel active ingredient afoxolaner, an isoxazoline based compound with a new and distinct mode of action. Merial is planning to make NexGard™ available to veterinarians in time for the upcoming flea and tick season.
Third-quarter sales of the Production Animals franchise reached €179 million, an increase of 0.5%.


Search News & Articles












Proudly associated with:
American Business Media Canadian Agri-Marketing Association National Agri-Marketing Association
Agricultural Relations Council National Association of Farm Broadcasters American Agricultural Editors' Association Livestock Publications Council
All content © Copyright 2014, Henderson Communications LLC. | User Agreement